CorWave is a medtech company that develops innovative cardiac support devices. CorWave’s membrane is based on disruptive technology, protected by nine patent families, resulting from over ten years of research in France’s National Scientific Research Centre (CNRS) labs and by AMS R&D. This technology stands out from other LVADs currently on the market due to its physiological design. Among other things, it is able to mimic a pulse and produce blood flow velocity similar to that of a healthy heart. Eventually, CorWave’s membrane pump technology should reduce complications associated with current devices and improve the care of patients with heart failure, a market potentially worth several billion euros.
Founded in 2012 by the incubator MD Start and supported by well-known investors, including Bpifrance, Novo Holdings, Seventure, Sofinnova and Ysios, CorWave has secured about €50 millions of financing and employs more than fifty people.